MorphoSys AG

MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
  • Ticker663200
  • ISINDE0006632003
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Victor Floc’h

MORPHOSYS: The right CEO to make MorphoSys a commercial-stage company | BUY | EUR125 vs. EUR120 (+18%)

MORPHOSYS - BUY | EUR125 vs. EUR120 (+18%) The right CEO to make MorphoSys a commercial-stage company Very positive first impression from meeting with new CEO Several catalysts could drive the stock in the coming months B-MIND futility analysis could lead to final data in Q1 2020 Could Astrazeneca be the right partner outside of the US?

Victor Floc’h

MORPHOSYS: The right CEO to make MorphoSys a commercial-stage company | BUY | EUR125 vs. EUR120 (+18%)

MORPHOSYS - BUY | EUR125 vs. EUR120 (+18%) The right CEO to make MorphoSys a commercial-stage company Very positive first impression from meeting with new CEO Several catalysts could drive the stock in the coming months B-MIND futility analysis could lead to final data in Q1 2020 Could Astrazeneca be the right partner outside of the US?

GSK zahlt MOR103-Meilenstein - Guidance angehoben

Die Guidance 2019 wurde durch den € 22 Mio.-Meilenstein von GSK am 03.07.19 angehoben: Jahresumsatzerlöse:  € 65 - € 72 Mio. (alt: € 43 - € 50 Mio.); das EBIT von € -105 bis € -115 Mio. (alt: € -127 bis € -137 Mio.) und der firmeneigene F&E-Aufwand mit unverändert € 95 - € 105 Mio. Das H1/19-EPS verbesserte sich von € -1,38 im Vj. auf nun € -0,90 (Q2/19-EPS: € -0,19). Die Entwicklung zum vollintegrierten Pharma-Unternehmen - mit dem Leadkandidaten MOR208 („Tafasitamab“) im Zentrum – nimmt Fahrt auf.

Eric Le Berrigaud

GSK/Morphosys: Otilimab: a phase III design with limited ambition

GSK/Morphosys Otilimab: a phase III design with limited ambition GSK appears shy with Otilimab An unclear positioning for GSK165 in a crowded market

Thomas J. Schiessle

Dr. J.-P. Kress ab 1.9.19 neuer CEO – sehr erfreuliche L-MIND-Primärdaten

Der künftige CEO „passt“ und bringt über 20 Jahre Branchenerfahrung in verschiedenen Senior Management-Positionen mit. Auch bei Pharma-Multis in Nordamerika und Europa entwickelte und vermarktete er innovative Antikörper-Produkte, zuletzt als CEO des jungen Autoimmun-Spezialisten Syntimmune GmbH, die 11/18 von Alexion übernommen wurde. Die Entwicklung zum vollintegrierten Pharma-Unternehmen - mit der Produktfamilie MOR208 im Zentrum – nimmt Fahrt auf. U.E. sehr erfreuliche Signale zur Gesamtüberlebenszeit aus Primäranalyse zur L-MIND wurden jüngst auf dem ICML 2019 in Lugano vorgestellt.

Gary Waanders

MORPHOSYS: Tafasitamab: additional L-MIND results presented at ICML | BUY | EUR120(+38%)

MORPHOSYS - BUY | EUR120(+38%) Tafasitamab: additional L-MIND results presented at ICML Tafasitamab activity in r/r DLBCL impresses on all counts Key L-MIND results Competitive profile in r/r DLBCL 2019 outlook

1 director bought

A director at Morphosys Ag bought 250 shares at 91.310EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Henning Steinbrink ...
  • Roland Pfaender,MBA,CFA,CCRA

Software AG : H1 2018 update of our ODDO BHF small/mid-cap Germany Conviction List

>Updating our Conviction List on German small-and mid-caps - We are updating our Conviction List for German small-and mid-cap companies selected from the ODDO BHF coverage universe. We believe companies on this list, selected on the basis of bottom-up, valuation and momentum considerations, have the potential to outperform their respective indices over an investment horizon of up to 12 months. We will continue to actively review our Conviction List, adding or remov...

MORPHOSYS AG sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to MORPHOSYS AG (DE), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date June 14, 2019, the closing price was EUR 89.05 and its target price was estimated at EUR 69.94.

Expert Corporate Governance Service (ECGS)

MorphoSys - AGM 22 May 2019

General: MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. It's Partnered Discovery segment business applies the Company's proprietary technologies to the research, development and optimisation of therapeutic antibody drug candidates in partnerschips with pharmaceutical and biotechnology companies. In the second segment, Proprietary Development, MorphoSys develops innovative proprietary antibody products. MorphoSys's scientists concentrate on indications such as inflammatory and autoimmune diseases, as well as cancer and infectious diseases. A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch